What to Know About Bimekizumab for HS: Update from James Q. Del Rosso, DO

01/16/25 • 10 min

Approved late last year to treat HS, bimekizumab was the subject of several publications in 2024, including phase 3 pivotal trial data. AARS President James Q. Del Rosso, DO gives an update on key data considerations. You can watch Dr. Del Rosso's full discussion of trial design, efficacy data, and safety findings online at acneandrosacea.org.

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!

Previous Episode

Laboratory Testing for Patients Taking Isotretinoin for Acne: Insights from Jonathan Weiss, MD

With a recent publication assessing the frequency of lab monitoring for patients with acne being treated with isotretinoin, AARS President Elect Jonathan Weiss, MD, FAAD, weighs in on the latest expert thinking. He also compares the current publication to the Guidelines of Care for Acne from the American Academy of Dermatology.

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!

Next Episode

Shedding Light on Devices for Acne: Update from Emmy Graber, MD

There are energy-based devices approved for the treatment of acne plus others with promising data. But there is some confusion about what works and what doesn't. AARS Treasurer Emmy Graber, MD provides an overview of findings from a recent study.

The American Acne and Rosacea Society (AARS) is the only professional society focused on acne, hidradenitis suppurativa, and rosacea. Support AARS by becoming a member!

AARS Hot Topics - What to Know About Bimekizumab for HS: Update from James Q. Del Rosso, DO

Transcript

This transcript has not been reviewed for accuracy and is provided as a courtesy only.

This is Hot Topics from the American Acne & Rosacea Society. Welcome to our first episode of 2025. Happy New Year.

This fall saw publications exploring the role of bimekizumab in the management of hidradenitis suppurativa. This followed publication of the Phase III trial results for bimekizumab in hidradenitis suppurativa in the Lancet in June. In November, the FDA approved Bimz